## **CLAIMS**

1. RANTES-derived peptides containing 10 to 19 amino acids, of formula (I):

5

10

15

## Ac-C-x1-PYI-x2-x3-Y-NH2 (I)

wherein Ac- represents an acetyl residue, -NH2 a carboxamido terminus, x1 and x3, which can be the same or different, are selected from the group consisting of the hydrophobic residues Phe, Tyr, 1Nal (L-beta-1-naphthyl-alanine), 2Nal (L-beta-2-naphthyl-alanine), Cha (L-beta-cyclohexyl-alanine), x2 is a spacer containing 2 to 12 amino acidic residues.

- 2. Peptides as claimed in claim 1, wherein x2 is selected from 1) the sequence 16-27 of RANTES, 2) the sequence 16-27 of RANTES in which 1 to 3 amino acidic residues are replaced with different natural or non natural L or D amino acids, 3) the sequence 16-27 of RANTES in which a group of at least two, preferably at least three and no more than nine residues, either consecutive or non consecutive, is removed.
- 3. Peptides as claimed in claim 1, in which x2 is selected from ARPLPR-X-HIKEYF, ARPLPR-X-HIKEY1Nal, ARPLPR-X-HIKEY2Nal, ARPLPR-X-HIKEYCha, ARPLPR-X-HIF, ARPLPR-X-HYF, ARPLPR-X-EYF,
- 20 ARPLPRKEYF, ARPLPIKEYF, ARP-X-HIKEYF, wherein X is Ala or Pro.
  - 4. Dimers of the peptides (I) in which two peptides are linked by disulfide bond between Cys residues at position 1.
  - 5. Pharmaceutical compositions containing as active ingredient a peptide (I) or a dimer thereof as claimed in the above claims.
- 25 6. Pharmaceutical compositions as claimed in claim 5, for use in the treatment of diseases in which the RANTES receptor is involved.
  - 7. The use of the peptides (I) or dimers thereof as claimed in claims 1-4 for the preparation of a medicament useful for the treatment of viral

infections, particularly HIV infections, and of inflammatory, allergic, degenerative, neoplastic or metastatic diseases.